D-SOLVE Cohorts (Cohort a and B)
Launched by HANNOVER MEDICAL SCHOOL · Nov 29, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The D-SOLVE study is a clinical trial aimed at understanding hepatitis D (HDV), a serious viral infection that can lead to severe liver problems, including liver failure and cancer. This research will involve a group of patients who are already infected with both hepatitis B and hepatitis D. By looking closely at these patients, the study hopes to identify specific markers in their blood that could help doctors personalize treatment plans, making them more effective and improving the overall quality of life for those affected by the disease.
To participate in this trial, individuals must be at least 18 years old and have a confirmed hepatitis D infection. Unfortunately, those who do not have hepatitis D will not be eligible. Participants will be part of a multi-center study, which means they will be collaborating with various medical centers. They can expect to undergo some tests and procedures that will help researchers learn more about how to better treat hepatitis D and its impact on patients' lives. This study is currently recruiting participants, and everyone, regardless of gender, is welcome to apply.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Anti-HDV positive
- • ≥18 years old
- • Sex: m/f/d
- • Informed consent for prospective procedures
- Exclusion Criteria:
- • Anti-HDV negative
About Hannover Medical School
Hannover Medical School (Medizinische Hochschule Hannover, MHH) is a leading academic medical institution in Germany, renowned for its commitment to innovative research and high-quality clinical care. Established in 1965, MHH specializes in a wide range of medical disciplines, with a strong focus on transplantation medicine, regenerative medicine, and personalized healthcare. The institution actively participates in clinical trials to advance medical knowledge and develop cutting-edge therapies, leveraging its state-of-the-art facilities and collaborative environment. With a dedicated team of researchers, clinicians, and support staff, Hannover Medical School aims to translate scientific findings into practical applications that improve patient outcomes and enhance the overall quality of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bucharest, , Romania
Hannover, , Germany
Milan, , Italy
Stockholm, , Sweden
Patients applied
Trial Officials
Markus Cornberg
Principal Investigator
Hannover Medical School
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported